References

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

10.1016/s2214-109x(13)70145-1 · 2014 · External reference

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study

10.1016/j.ophtha.2008.10.018 · 2009 · External reference

Ranibizumab for neovascular age-related macular degeneration

10.1056/nejmoa054481 · 2006 · External reference

Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration

10.1016/j.ophtha.2012.09.006 · 2012 · External reference

Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration

2018 · External reference

Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study

10.1016/j.ajo.2018.08.026 · 2019 · External reference

HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration

10.1016/j.ophtha.2019.04.017 · 2020 · External reference

Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade

10.1038/s41433-020-0895-z · 2020 · External reference

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration—a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems

10.1186/s12886-020-01554-2 · 2020 · External reference

Visual impairment certification secondary to ARMD in Leeds, 2005–2010: is the incidence falling?

10.1038/eye.2012.61 · 2012 · External reference

Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-related Macular Degeneration Treatments Trials

10.1016/j.ophtha.2016.03.045 · 2016 · External reference

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

10.1016/j.ophtha.2012.03.053 · 2012 · External reference

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

10.1136/bjophthalmol-2014-305327 · 2015 · External reference

Lifetime outcomes of anti–vascular endothelial growth factor treatment for neovascular age-related macular degeneration

10.1001/jamaophthalmol.2020.3989 · 2020 · External reference

Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration

10.1097/iae.0000000000001142 · 2016 · External reference

Visual acuity outcomes and anti–vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes

10.1016/j.oret.2019.05.017 · 2020 · External reference

Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration

10.1371/journal.pone.0129361 · 2015 · External reference

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey

10.2147/opth.s92548 · 2015 · External reference

Sierra-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States

10.1016/j.oret.2019.09.009 · 2020 · External reference

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

10.1016/j.ophtha.2010.09.004 · 2011 · External reference

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2

10.1016/j.ajo.2010.04.011 · 2010 · External reference

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1

10.1016/j.ajo.2007.10.004 · 2008 · External reference

Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data

10.1038/s41433-020-01377-x · 2021 · External reference

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

10.1016/j.ophtha.2013.08.011 · 2014 · External reference

Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases

10.15252/emmm.201505889 · 2016 · External reference

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

10.1073/pnas.1019002108 · 2011 · External reference

Phase I trial of anti–vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration

10.1016/j.oret.2017.03.003 · 2017 · External reference

Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial

10.1001/jamaophthalmol.2020.2685 · 2020 · External reference

Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial

10.1001/jamaophthalmol.2020.2699 · 2020 · External reference

Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature study group

10.1016/j.ophtha.2019.11.004 · 2020 · External reference

Efficacy of simultaneous VEGF-A/Ang-2 neutralization in suppressing spontaneous choroidal neovascularization

10.15252/emmm.201810204 · 2019 · External reference

Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol

10.1016/j.ophtha.2014.07.041 · 2015 · External reference

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

10.1016/j.ophtha.2012.10.014 · 2013 · External reference

Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients

10.3390/vision3030041 · 2019 · External reference

Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results

10.1016/j.ophtha.2015.08.009 · 2015 · External reference

Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study

10.1016/j.oret.2016.12.004 · 2017 · External reference

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

10.1016/j.ophtha.2014.05.009 · 2014 · External reference

Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study

10.1007/s00417-019-04404-0 · 2019 · External reference

Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial

10.1001/jamaophthalmol.2019.5540 · 2020 · External reference

Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations

10.1097/iae.0000000000000627 · 2015 · External reference

Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial

10.1007/s12325-020-01236-x · 2020 · External reference

Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison

10.1007/s12325-020-01298-x · 2020 · External reference

Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study

10.1016/j.ophtha.2017.07.014 · 2018 · External reference

Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial

10.1001/jamaophthalmol.2018.6776 · 2019 · External reference

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting

10.1186/s12886-017-0451-1 · 2017 · External reference

Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration

10.1016/j.ophtha.2008.08.016 · 2008 · External reference

Quantification of choroidal neovascularization vessel length using optical coherence tomography angiography

10.1117/1.jbo.21.7.076010 · 2016 · External reference